AcquiredKRASmutations are a known mechanism of resistance observed across driver mutation-positive (DM+) NSCLC. The incidence and diversity of these acquired alterations, and whether they differ from those observed inde novoKRAS-mutated NSCLC, is unknown.Methods:NSCLC molecular profiles were obtained ...
Mutational landscape of 50KRAS-positive Chinese colorectal cancer (CRC) patients and Western patients. (a) Proportions ofKRASmutation subtypes. The data of Western patients were obtained from TCGA-COAD and TCGA- READ (n = 209). G12D, OR = 2.208, 95% confidence intervals (CI) =...
G12V, G12C, G12R and G13D was generated by in silico aided antigen design. KRAS mutation specific CD8+ T cell expansion was evaluated in HLA transgenic mice treated with HB-700 and functionality of induced CD8+ T cells was evaluated by assessing CD8+ T cell mediated killing of mutant KR...
Cooperating gene mutations (including c-KIT, FLT3 and N/KRAS, etc.) enhance the proliferative potential of the preleukemic cells as ‘second hit’ and eventually causes full-blown leukemia [3]. Additional pathological mechanisms, such as epigenetic regulation, work in collaboration to facilitate ...
Among the 208 MSI-H CRCs, 7 cases were excluded from KRAS mutation analysis, owing to an insufficient amount or poor quality of the isolated DNA. Statistical analysis. All statistical analyses were performed using IBM SPSS statistics version 20 (IBM, Armonk, NY, USA). The w2-test or Fisher...
33,34 However, we also have identified a novel finding of an acquired KRAS mutation, which was confirmed using tumor NGS and plasma droplet digital PCR. The complex variety of resistance mutations seen in patients with loss of T790M, including several acquired fusion genes, highlights the need ...
Subscriptions Alpha Picks Premium & Pro Group SubscriptionsSearch field Entering text into the input field will update the search result below About Premium Create free account Log inSeeking Alpha - Power to Investors Power to Investors Follow us Download app ...
KRAS mutations EGFR-Positive Lung Cancer Treatment EGFR-positive lung cancer is usually treated with FDA-approvedtargeted therapy drugs.10This is a change from how they were treated historically whenchemotherapywas the first course of treatment for almost all cases of advanced non-small cell lung can...
F. et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin. Cancer Res. 19, 4273–4281 (2013). Article CAS PubMed Google Scholar Sasaki, T. et al. A novel ALK secondary mutation and EGFR ...
Multiple confirmed partial responses by RECIST 1.1 harbor genetic co-alterations, including MTAP-deletion and KRAS G12D mutation in NSCLC, and MTAP-deletion and FGFR-TACC3 fusion in UC ~93% Disease Con...